Long lasting contrast agent testing in the context of SPCCT project

Voxcan proudly takes its place as a referenced company for CT and SPCCT contrast agent validation.

In a new study, scientists from Claude Bernard Lyon 1 University, in collaboration with VOXCAN and with European H2020 consortium (SPCCT Project), have developed concentrated suspensions of nanoparticles residing longer in the circulatory system than existing commercial contrast agents. The new nanoparticles designed in iodinated polymer benefit from a residence time of several hours, offering the possibility of visualizing the circulatory system during the long duration of a medical intervention. Another benefit is the possibility of accumulation of the contrast agent in pathological areas.

These results obtained by experiments on rats and published in Biomaterials Science journal constitute the first step towards potential clinical applications in humans.